Targets › AHR
2 programs from 2 companies in 4 trials: 2 Phase 2, 2 Phase 3; Immunology; next expected readout Aug 2027.
Ligand-activated transcription factor that enables cells to adapt to changing conditions by sensing compounds from the environment, diet, microbiome and cellular metabolism, and which plays important roles in development, immunity and cancer. Upon ligand binding, translocates into the nucleus, where it heterodimerizes with ARNT and induces transcription by binding to xenobiotic response elements (XRE). (UniProt, P35869)
Open in Phaseline: the race on AHR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Organon and | Tapinarof Aryl hydrocarbon receptor agonist | AHR | Phase 3 | Plaque Psoriasis; Atopic Dermatitis; Palmoplantar Keratoderma | Aug 2027 |
| Birch BioMed | FS2 Kynurenic acid, aryl hydrocarbon receptor (AhR) agonist | AHR | Phase 2 | Burn Scar | Sep 2027 |
Burn Scar (1) Plaque Psoriasis (1) Atopic Dermatitis (1) Palmoplantar Keratoderma (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.